Literature DB >> 9669344

Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.

A S Chan1, S Y Leung, M P Wong, S T Yuen, N Cheung, Y W Fan, L P Chung.   

Abstract

Vascular endothelial growth factor (VEGF) is a hypoxia-inducible angiogenic factor, which is known to be upregulated in most cases of glioblastoma multiforme (GBM). The expression of VEGF and its receptors in ependymomas, oligodendrogliomas, and particularly the expression during anaplastic progression of these three types of gliomas has not been studied extensively. Fifty-six gliomas, consisting of 10 ependymomas, 12 oligodendrogliomas, 3 anaplastic oligodendrogliomas, 6 astrocytomas grade II, 5 anaplastic astrocytomas, and 20 glioblastoma multiformes, were investigated for VEGF and receptor expression using in situ hybridization (ISH) and reverse transcription polymerase chain reaction (RT-PCR). Results showed that VEGF was moderately to strongly expressed in 8 of 10 ependymomas and in all anaplastic oligodendrogliomas and glioblastoma multiforme cases. These tumors displayed similar degrees of extensive necrosis and vascular proliferation, with VEGF expression consistently seen in tumor cells around necrotic areas. The VEGF expression, although present at a lower level, also was shown in 4 of 12 oligodendrogliomas, in 3 of 6 astrocytomas grade II, and in 2 of 5 anaplastic astrocytomas, with a regional rather than diffuse pattern of positive result. The findings from the in situ hybridization study correlated with the expression index, as determined by reverse transcription polymerase chain reaction. Expression of VEGF was correlated significantly with vascular proliferation (p < 10(-5)) and necrosis (p < 10(-5)), as well as with microvessel density (p = 0.002, rs = 0.41). The VEGF receptors, kinase domain region (KDR) and Fms-like-tyrosine kinase (Flt-1), also were upregulated in the tumor vasculature of glioblastoma multiforme, anaplastic oligodendrogliomas, and ependymomas with necrosis, whereas the astrocytomas grade II, anaplastic astrocytomas, and oligodendroglioma tumors tended to express a weak to nondetectable signal. Anaplastic progression in all three types of gliomas is heralded by the occurrence of small zones of VEGF-expressing cells and early vascular proliferation, followed by an accelerated phase of angiogenesis closely associated with VEGF induction around areas of necrosis and with the expression of VEGF receptors in the tumor vasculature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669344     DOI: 10.1097/00000478-199807000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  53 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  PRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling.

Authors:  Peter Noy; Hannah Williams; Anyaporn Sawasdichai; Kevin Gaston; Padma-Sheela Jayaraman
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

Review 3.  Update on brain tumor imaging: from anatomy to physiology.

Authors:  S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2006-03       Impact factor: 3.825

4.  MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas.

Authors:  Antonio C M Maia; Suzana M F Malheiros; Antonio J da Rocha; Carlos J da Silva; Alberto A Gabbai; Fernando A P Ferraz; João N Stávale
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

5.  A continuous-infusion dynamic MRI model at 3.0 Tesla for the serial quantitative evaluation of microvascular proliferation in an animal model of glioblastoma multiforme.

Authors:  Hunter R Underhill
Journal:  Magn Reson Med       Date:  2017-01-12       Impact factor: 4.668

6.  Prognostic marker analysis in pediatric intracranial ependymomas.

Authors:  Roger E McLendon; Eric Lipp; Diane Satterfield; Melissa Ehinger; Alan Austin; Debra Fleming; Kathryn Perkinson; Michaela Lefaivre; David Zagzag; Benjamin Wiener; Sri Gururangan; Herbert Fuchs; Henry S Friedman; James E Herndon; Patrick Healy
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

7.  Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Authors:  Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

8.  Anaplastic oligo-astrocytoma occurring after resection of a cerebral cavernous malformation; malignant transformation? Case report and review on etiology.

Authors:  Tobien Schreuder; Merijn Te Lintelo; Bela Kubat; Peter Koehler
Journal:  J Neurol       Date:  2009-09-24       Impact factor: 4.849

9.  Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

Authors:  H Quon; A Hasbini; J Cougnard; L Djafari; C Lacroix; B Abdulkarim
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

10.  Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.

Authors:  József Virág; István Kenessey; Christine Haberler; Violetta Piurkó; Katalin Bálint; Balázs Döme; József Tímár; Miklós Garami; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2013-11-05       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.